https://orcid.org/0000-0002-7869-7181
REFERENCES
- Chow, S.-C., and J.-P. Liu. 2014. Sample size determination. In Design and analysis of clinical trials: Concepts and methodologies, 3rd ed., 441–518. Hoboken, NJ: John Wiley & Sons.
- Davila, M. L., I. Riviere, X. Wang, et al. 2014. Efficacy and toxicity management of 19–28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Science Translational Medicine 6 (224):1–10. doi:10.1126/scitranslmed.3008226.
- Jecker, N. S., A. G. Wightman, A. R. Rosenberg, and D. S. Diekema. 2017. From protection to entitlement: Selecting research subjects for early phase clinical trials involving breakthrough therapies. Journal of Medical Ethics 43 (6):391–400. doi:10.1136/medethics-2016-103868.
- Jecker, N. S., A. G. Wightman, A. R. Rosenberg, and D. S. Diekema. 2018. Ethical guidance for selecting clinical trials to receive limited space in an immunotherapy production facility. American Journal of Bioethics 18 (4):58–67.
- Lee, D. W., J. N. Kochenderfer, M. Stetler-Stevenson, et al. 2015. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial. Lancet 385 (9967):517–28. doi:10.1016/S0140-6736(14)61403-3.
- Piantadosi, S. 2017. Clinical trials: A methodologic perspective. Wiley Series in Probability and Statistics. Hoboken, NJ: Wiley.
- Sanders, D., and J. Dukeminier. 1968. Medical advance and legal lag: Hemodialysis and kidney transplantation. UCLA Law Review 15:357–413.